Premium
Residual tumor cells are unique cellular targets in glioblastoma
Author(s) -
Glas Martin,
Rath Barbara H.,
Simon Matthias,
Reinartz Roman,
Schramme Anja,
Trageser Daniel,
Eisenreich Ramona,
Leinhaas Anke,
Keller Mihaela,
Schildhaus HansUlrich,
Garbe Stephan,
Steinfarz Barbara,
Pietsch Torsten,
Steindler Dennis A.,
Schramm Johannes,
Herrlinger Ulrich,
Brüstle Oliver,
Scheffler Björn
Publication year - 2010
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22036
Subject(s) - glioblastoma , brain tumor , stem cell , cancer research , biopsy , in vitro , pathology , minimal residual disease , tumor cells , biology , neurosurgery , resection , cell culture , drug resistance , medicine , microbiology and biotechnology , surgery , bone marrow , biochemistry , genetics
Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection. Their resistance to postsurgical therapy is considered a major driving force of mortality, but their biology remains largely uncharacterized. In this study, residual tumor cells were derived via experimental biopsy of the resection margin after standard neurosurgery for direct comparison with samples from the routinely resected tumor tissue. In vitro analysis of proliferation, invasion, stem cell qualities, GBM‐typical antigens, genotypes, and in vitro drug and irradiation challenge studies revealed these cells as unique entities. Our findings suggest a need for characterization of residual tumor cells to optimize diagnosis and treatment of GBM. ANN NEUROL 2010;68:264–269